newsfilter
← Latest News
ACCESS Newswire·

Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

~ Engineered to Deliver Potent Pain Relief with Unique, Built-In, Abuse Protection ~ SAN DIEGO, CA / ACCESS Newswire / December 9, 2025 / Ensysce Biosciences, Inc. ("Ensysce" or the